Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06390358 · ClinicalTrials.gov registry record · NA
Effects of Remote Cardiac Ischemic Preconditioning
A NA study of Cardiac Function and Preconditioning, sponsored by Jack Rubinstein.
- Recruiting
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06390358 is a NA study of Cardiac Function and Preconditioning that is actively recruiting participants, run by Jack Rubinstein. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06390358, a NA study of Cardiac Function and Preconditioning, is actively recruiting participants, sponsored by Jack Rubinstein.
- RECRUITING
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
A heart attack occurs when blood flow is disrupted to the heart and is related to both the blockage and flow restoration (reperfusion injury). An occlusion during a heart attack can be cleared (mostly via stents), but there are no methods to decrease reperfusion injury even though animal studies have found that "preconditioning" has powerful protective effects. Through the observation of Jewish men wearing tefillin the investigators have discovered a method of bringing preconditioning to patients at risk for heart attacks. This study will focus on women as the majority of people who wear tefillin (and have been studied) are men.
Conditions Studied
Interventions
- OTHER Tefillin
Study Locations (1)
Ohio
- University of Cincinnati - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2025-05-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06390358
The ClinicalTrials.gov registry entry for NCT06390358 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jack Rubinstein, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cardiac Function and Preconditioning appearing as the primary indexed condition, and to 1 intervention - of which Tefillin is the first listed.
NCT06390358 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06390358 about?
NCT06390358 is a clinical study titled "Effects of Remote Cardiac Ischemic Preconditioning". A heart attack occurs when blood flow is disrupted to the heart and is related to both the blockage and flow restoration (reperfusion injury). An occlusion during a heart attack can be cleared (mostly via stents), but there are no methods to decrease reperfusion injury even though animal studies hav...
What is the current status of trial NCT06390358?
This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2024-05-01. Estimated completion is 2025-05-01.
What conditions does trial NCT06390358 study?
This clinical trial studies the following conditions: Cardiac Function and Preconditioning.
What interventions are being tested in trial NCT06390358?
The interventions under investigation include: Tefillin (OTHER).
Who is sponsoring clinical trial NCT06390358?
This trial is sponsored by Jack Rubinstein, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06390358 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.